Lupin appoints Brian Savage as President and Chief Legal Officer

Management Changes View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹1922.00

prior close

₹1922.00

announcement price

After-mkt

timing

Nifty Midcap 150market-2.1%+2.4% vs market

Pharmaceuticals peers, median of 170sector-1.6%+1.9% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.4

15m

-0.4

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4-2.1+2.4-1.6+1.9

Next day

+2.0-1.0+3.0-0.5+2.4

+1.6-0.1+1.7+1.5+0.0

+2.7+0.2+2.5+2.5+0.2

+3.5+1.0+2.5+2.7+0.9

+4.6pendingpending+1.5+3.1

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin appointed Brian Savage as President and Chief Legal Officer effective October 22, 2026. He will oversee global legal, compliance and intellectual property functions. Savage previously held senior legal roles at Teva Pharmaceuticals, including Executive Vice President and interim Global Chief Legal Officer.

Likely market impact

The appointment may strengthen legal oversight and compliance, but the filing gives no financial guidance or indication of an immediate stock impact.